Loading...
01/09 22:52
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. While there are positive aspects like raised revenue guidance and strategic acquisitions, there are concerns such as negative free cash flow and management's vague responses on long-term strategies and impacts of MSN. The Q&A section highlights stable performance but lacks strong catalysts for immediate growth. Overall, the sentiment is balanced by positive and negative elements, leading to a neutral prediction for stock price movement.
Consolidated Revenues $97.8 billion, an increase of 23% over the prior year. This growth was driven by increased prescription volumes, the addition of a strategic account customer, growth of GLP-1 medications, and growth in the distribution of oncology and specialty products.
Adjusted Operating Profit $1.4 billion, an increase of 9% year-over-year. Growth was supported by strong oncology and multi-specialty volumes, increased demand for access solutions, and benefits from cost optimization initiatives.
Gross Profit $3.3 billion, an increase of 7% year-over-year. Growth was driven by specialty distribution and provider growth within the U.S. Pharmaceutical segment and growth in the Prescription Technology Solutions segment.
Operating Expenses $1.9 billion, a decrease of 1% year-over-year. This was driven by divestitures in the Canadian business and cost optimization initiatives in the Medical-Surgical Solutions segment.
U.S. Pharmaceutical Revenues $90 billion, an increase of 25% year-over-year. Growth was driven by increased prescription volumes, growth in the distribution of oncology and specialty products, and contributions from acquisitions.
GLP-1 Medications Revenue $12.1 billion, an increase of approximately $3.3 billion or 38% year-over-year. Sequentially, GLP-1 revenue increased 11%.
Prescription Technology Solutions Revenue $1.4 billion, an increase of 16% year-over-year. Growth was driven by increased prescription volumes in the third-party logistics business.
Prescription Technology Solutions Operating Profit $269 million, an increase of 21% year-over-year. Growth was driven by higher demand for access solutions, including prior authorization services for GLP-1 medications.
Medical-Surgical Solutions Revenue $2.7 billion, an increase of 2% year-over-year. Growth was driven by higher volumes of Specialty Pharmaceuticals.
Medical-Surgical Solutions Operating Profit $244 million, an increase of 22% year-over-year. Growth was driven by operational efficiencies from cost optimization initiatives.
International Revenues $3.7 billion, an increase of 1% year-over-year. Growth was driven by higher pharmaceutical distribution volumes in the Canadian business, partially offset by divestitures.
International Operating Profit $99 million, a decrease of 3% year-over-year. This was driven by the divestiture of the Canada-based Rexall and Well.ca businesses.
Corporate Expenses $138 million, a 4% decrease year-over-year when excluding McKesson Ventures gains. This was driven by lower opioid-related expenses and technology costs.
Free Cash Flow Negative $1.1 billion, which included $189 million in capital expenditures and $3.4 billion of cash used for acquisitions.
Oncology and Biopharma Services: McKesson completed the acquisition of a controlling interest in Core Ventures and PRISM Vision, expanding its oncology and retina/ophthalmology platforms. These acquisitions enhance practice management solutions and broaden the U.S. Oncology Network to 3,300 providers across 700 sites in 30 states.
Prescription Technology Solutions: The segment delivered double-digit growth in revenue and adjusted operating profit, driven by increased demand for access and affordability solutions, including prior authorization services for GLP-1 medications.
Expansion in Oncology and Specialty Pharmaceuticals: McKesson expanded its U.S. Oncology Network and cold chain capabilities to support specialty therapies. The company also hosted its annual IdeAShare conference to strengthen ties with community pharmacies.
International Market Exit: McKesson entered into a definitive agreement to sell its retail and distribution businesses in Norway, marking the final phase of its European market exit.
Automation and Technology Investments: McKesson implemented automated storage, retrieval, and picking systems across its distribution centers, achieving up to 90% automation in some facilities. These advancements improved productivity, quality, and safety.
Cold Chain Capabilities: The company expanded its cold chain capabilities, resulting in nearly double-digit growth in cold chain lines year-over-year.
Portfolio Management: McKesson announced the separation of its Medical-Surgical segment into an independent company to enhance operational focus and unlock value.
European Market Strategy: The planned exit from Norway completes McKesson's strategy to divest its European businesses, aligning with its focus on North American operations.
Regulatory Approvals: The sale of the retail and distribution businesses in Norway is subject to customary closing conditions, including receipt of required regulatory approvals. Delays or failure in obtaining these approvals could impact the transaction timeline and financial outcomes.
Bad Debt Provision: A GAAP-only pretax provision for bad debts of $189 million was recorded due to Rite Aid's second bankruptcy filing. This represents a financial risk related to outstanding trade accounts receivable balances.
Integration Challenges: The integration of recent acquisitions, such as PRISM Vision and Core Ventures, remains ongoing. Challenges in integration could impact operational efficiency and expected synergies.
Supply Chain Complexity: Operating a large-scale distribution network involves complexities, including the implementation of automated technologies and processes. Any disruptions or inefficiencies in these systems could affect productivity and safety.
Cold Chain Capabilities: The growing demand for specialty therapies requiring cold chain capabilities adds pressure to maintain product integrity and supply chain resiliency. Failures in this area could lead to financial and reputational risks.
Divestiture Risks: The planned exit of the Norway business and the separation of the Medical-Surgical segment into an independent company involve significant operational and strategic execution risks.
Market and Policy Environment: The company is navigating a dynamic market and policy environment, which could impact its business and customer relationships. Changes in policies or market conditions could pose risks to operations.
GLP-1 Medication Growth Variability: While GLP-1 medications have shown growth, this growth may vary from quarter to quarter, introducing revenue unpredictability.
Technology Investments: Investments in automation and advanced technologies are critical but come with risks of implementation delays or failures, which could impact operational efficiency.
European Business Exit: The planned exit from European operations, including the Norway business, marks the final phase of divestitures. Any delays or issues in this process could impact financial outcomes and strategic focus.
Full Year Guidance Update: The company raised its full-year guidance to $37.10 to $37.90 from a previous range of $36.90 to $37.70, reflecting confidence in continued strong performance.
Revenue Growth: Anticipated revenue growth of 11% to 15% for fiscal 2026, driven by strong performance across operating segments.
Operating Profit Growth: Expected operating profit growth of 9% to 13% for fiscal 2026, supported by strategic acquisitions and operational efficiencies.
U.S. Pharmaceutical Segment: Revenues are expected to increase by 12% to 16%, with operating profits anticipated to grow at the high end of the 12% to 16% range. Growth will be driven by GLP-1 medications, oncology, and specialty products.
Prescription Technology Solutions Segment: Revenues are projected to grow by 8% to 12%, with operating profit increasing by 9% to 13%. Growth will be supported by increased demand for access and affordability solutions, including prior authorization services for GLP-1 medications.
Medical-Surgical Solutions Segment: Revenues and operating profit are expected to grow by 2% to 6%, driven by cost optimization initiatives and operational efficiencies.
International Segment: Revenues are projected to range from a 2% decline to 2% growth, with operating profit expected to increase by 3% to 7%. Growth in Canadian distribution will offset the impact of divestitures.
Strategic Acquisitions: The acquisitions of PRISM Vision and Core Ventures are expected to contribute approximately 6% to 7% to fiscal 2026 operating profit growth in the U.S. Pharmaceutical segment.
Capital Deployment: Plans to repurchase approximately $2.5 billion of shares in fiscal 2026 and a 15% increase in the quarterly dividend approved by the Board of Directors.
Free Cash Flow: Anticipated free cash flow of approximately $4.4 billion to $4.8 billion for fiscal 2026.
Dividend Payments: McKesson returned $671 million of cash to shareholders, which included $90 million in dividend payments.
Dividend Increase: In July, the Board of Directors approved a 15% increase to the quarterly dividend.
Share Repurchases: McKesson returned $671 million of cash to shareholders, which included $581 million in share repurchases.
Planned Share Repurchases: The company plans to repurchase approximately $2.5 billion of shares in fiscal 2026.
The earnings call summary indicates strong financial performance with raised guidance, robust revenue and operating profit growth, strategic acquisitions, and shareholder returns through share repurchases and dividend hikes. The Q&A section highlights positive analyst sentiment, with strong specialty volume trends and effective margin management. Despite some nonrecurring gains and vague responses, the overall sentiment remains positive. The raised guidance and strategic initiatives suggest a likely stock price increase, making a positive rating appropriate.
The earnings call presents a mixed picture. While there are positive aspects like raised revenue guidance and strategic acquisitions, there are concerns such as negative free cash flow and management's vague responses on long-term strategies and impacts of MSN. The Q&A section highlights stable performance but lacks strong catalysts for immediate growth. Overall, the sentiment is balanced by positive and negative elements, leading to a neutral prediction for stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
